Cite
HARVARD Citation
Jemec, G. et al. (2019). Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials. British journal of dermatology. pp. 967-975. [Online].